Sava raises $19m in Series A funding led by Balderton Capital and Pentland Ventures to advance wearable biosensor technology
The London healthtech startup secured backing from Balderton and Pentland to scale manufacturing and regulatory pathways for its continuous glucose monitor.
≈ £14.4M at $1 = £0.7571 on 31 Jul 2025
London-based health technology startup developing real-time and pain-free microsensors for continuous health monitoring.
London-based healthtech startup Sava has secured $19m in Series A funding to scale up manufacturing, grow its team, and advance regulatory approval for its continuous glucose monitor. The round was led by Balderton Capital and Pentland Ventures, with additional participation from Norrsken VC, JamJar Investments, True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures.
The capital follows a clinical study of the startup's multi-molecule microsensor technology in Oxford and Cambridge. The funding brings the firm's total capital raised to $32m, following previous support from angels, the European Union, and the British government.
Sava is positioning its device as a less invasive, cost-effective alternative to established market options. The firm plans to expand its headcount, which has already grown past 60 personnel.
From the founder
"During their time at Imperial, they worked in one of the pioneering research groups that invented modern glucose strip technology. Their combined expertise in electrochemistry, biosensing, and medical device engineering laid the foundation for Sava’s next-generation biosensor platform."
Renato Circi
Co-founder and Co-CEO at SAVA
Investor perspective
"Understanding what’s going on in our bodies is the first step to improving our health"
James Wise
Partner, Balderton
Use of funds
- 01Grow the team
- 02Expand into international markets
- 03Scale operations
Investors
James Wise
Balderton
Pentland
Norrsken
JamJar
True
Italian Founders Fund
Athletico Ventures
Exceptional Capital